Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Galena Biopharma Inc. and Encourages Investors to Contact the Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Galena Biopharma Inc. and Encourages Investors to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Galena Biopharma Inc. (“Galena” or the “Company”) (Nasdaq: GALE) concerning possible violations of federal securities laws.

If you purchased shares of Galena and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

Galena announced plans to “divest its commercial business,” which included the Company’s innovative cancer pain drug, Abstral. On March 10, 2016, the Company disclosed that “[a] federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes,” and that the Company was issued a trial subpoena for documents related to that investigation. The Company also noted that “other governmental agencies may be investigating our Abstral promotion practices,” and that “on December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral.”

On January 31, 2017, Galena announced that Mark W. Schwartz, President and Chief Executive Officer during this time, was resigning from his position.

When this information was revealed to the investing public, the value of Galena fell significantly, causing investors harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today